NCT02970552View on ClinicalTrials.gov

Feasibility of Vaginal Progesterone to Reduce HIV-Associated Preterm Birth

PHASE4CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

November 13, 2018

Study Completion Date

November 13, 2018

Conditions
PreTerm Birth
Interventions
DRUG

Vaginal Progesterone

200 mg micronized vaginal progesterone suppository

DRUG

Placebo

Indistinguishable placebo vaginal suppository

Trial Locations (1)

Unknown

Kamwala District Health Centre, Lusaka

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT02970552 - Feasibility of Vaginal Progesterone to Reduce HIV-Associated Preterm Birth | Biotech Hunter | Biotech Hunter